News

The latest press releases, publications, and events for Innoviva Specialty Therapeutics

Filter by:

All News Press Releases Events

07.31.2025

Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance

Read More

07.31.2025

Update on the Activity of Ceftobiprole against Gram-positive Clinical Bacterial Isolates Causing Skin and Skin-structure Infections in the United States (2016–2020)

Read More

07.31.2025

In vitro Activity of Ceftobiprole Against Prominent Methicillin-resistant Staphylococcus aureus Clonal Groups Collected Through the SENTRY Antimicrobial Surveillance Program

Read More

06.11.2025

In Vitro activity of ceftobiprole against 20,255 recent clinical bacterial isolates in Canada (CANWARD 2015-2023)

Read More

05.08.2025

Ceftobiprole: A therapeutic update

Read More

05.01.2025

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients

Read More

05.01.2025

Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients

Read More

04.02.2025

Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials

Read More

04.01.2025

Ceftobiprole activity against multidrug-resistant Staphylococcus aureus clinical isolates collected in the United States from 2016 through 2022

Read More

02.25.2025

Efficacy and safety of ceftobiprole in patients aged 65 years or older: a post hoc analysis of three Phase III studies

Read More